The Alzheimer's Association International Conference (AAIC) 2026 showcased transformative advances in molecular neuroimaging for Alzheimer's disease, featuring:
These advances represent a paradigm shift toward biologically-defined AD diagnosis and treatment selection, moving beyond clinical criteria alone.
Amyloid PET has evolved significantly since the introduction of Pittsburgh Compound-B (PiB) in 2004[1]:
| Generation | Tracers | Key Advances |
|---|---|---|
| First-generation | 11C-PiB, 18F-florbetapir, 18F-flutemetamol, 18F-florbetaben | Clinical approval, validation |
| Second-generation | Improved 18F-tracers with better kinetics | Faster clearance, reduced off-target |
The Centiloid (CL) scale has become the standard metric for amyloid quantification[2]:
AAIC 2026 featured advances in amyloid PET technology:
| Tracer | Characteristics | Status |
|---|---|---|
| 18F-Florbetapir (Amyvid) | FDA-approved, widely used | Clinical standard |
| 18F-Flutemetamol (Vizamyl) | FDA-approved, thioflavin analog | Clinical standard |
| 18F-Florbetaben (Neuraceq) | FDA-approved for beta-amyloid | Clinical standard |
| 18F-AK01 | Improved signal-to-noise | Phase 3 |
Amyloid PET is essential for patient selection and treatment monitoring:
| Therapy | Amyloid PET Requirement | Monitoring |
|---|---|---|
| Lecanemab (Leqembi) | Amyloid-positive MCI or AD | SUVr reduction at 18 months |
| Donanemab | Amyloid-positive early AD | Plaque clearance (CL < 10) |
| Aducanumab | Amyloid-positive AD | Dose selection, target engagement |
AAIC 2026 highlighted the transition from first to second-generation tau PET agents[3]:
| Property | First-Generation | Second-Generation |
|---|---|---|
| Off-target binding | High (basal ganglia, choroid plexus) | Minimal |
| Quantification | Complex SUVr methods | Simplified visual read |
| Disease applicability | AD only | AD + primary tauopathies |
| Early detection | Limited | Preclinical detection |
Flortaucipir (Tauvid, 18F-AV-1451)
| Tracer | Developer | Key Features | Status |
|---|---|---|---|
| MK-6240 | Merck | Higher PHF-tau specificity | Phase 3 |
| PI-2620 | Life Molecular Imaging | 3R/4R detection (PSP, CBD) | Phase 2/3 |
| APN-1607 | Aprinoia | Broad tauopathy applicability | Phase 2 |
| RO-948 | Roche | Early detection | Phase 2 |
| JNJ-311 | J&J | Novel binding profile | Phase 1 |
Tau PET enables in vivo Braak staging:
| Braak Stage | Regions Affected | Clinical Correlation |
|---|---|---|
| I-II | Transentorhinal cortex | Preclinical AD |
| III-IV | Limbic (hippocampus, entorhinal) | MCI to mild AD |
| V-VI | Isocortical (frontal, parietal) | Moderate to severe AD |
Tau PET serves as both enrichment biomarker and outcome measure:
| Trial Phase | Tau PET Application |
|---|---|
| Phase 1 | Target engagement, dose selection |
| Phase 2 | Patient stratification, mechanism validation |
| Phase 3 | Disease modification endpoints |
AAIC 2026 Anti-Tau Updates:
AAIC 2026 featured major advances in blood-based biomarkers[4]:
| Biomarker | Current Status | Clinical Utility |
|---|---|---|
| p-Tau217 | FDA review pending | Highest specificity, >95% sensitivity |
| p-Tau181 | FDA-cleared (multiple platforms) | Widely available, screening |
| p-Tau231 | Research stage | Earliest detectable marker |
| GFAP | FDA-cleared | Astrocyte activation, amyloid reactivity |
Blood biomarkers demonstrate exceptional performance[5]:
| Panel Composition | AUC for AD vs. Controls |
|---|---|
| p-tau217 + GFAP | 0.95-0.97 |
| p-tau181 + NfL | 0.92-0.94 |
| p-tau217 + GFAP + NfL | 0.96-0.98 |
| p-tau217 + GFAP + Aβ42/40 | 0.97-0.99 |
| PET Measure | Fluid Biomarker Correlation |
|---|---|
| Amyloid PET (Centiloid) | p-tau217 (r=0.82-0.89), Aβ42/40 (r=0.75-0.85) |
| Tau PET (Braak ROI) | p-tau217 (r=0.78-0.86), p-tau181 (r=0.70-0.80) |
| Neurodegeneration (FDG-PET) | NfL (r=0.65-0.75), p-tau181 (r=0.60-0.70) |
The AT(N) framework has evolved to incorporate blood-based markers[6]:
| Scenario | Recommended Biomarkers |
|---|---|
| Routine screening | p-tau181 (primary care) |
| Confirmatory testing | p-tau217 (specialty) |
| Comprehensive assessment | Full AT(N) panel + PET |
| Treatment selection | Amyloid PET required |
| Treatment monitoring | p-tau217, NfL, amyloid PET |
FDA pathway updates:
Two-tiered clinical approach:
| Technology | Potential Impact |
|---|---|
| Point-of-care lateral flow assays | Primary care screening |
| Dried blood spot testing | Broader accessibility |
| Tau oligomer detection | Earlier, more specific detection |
| Exosomal tau | Brain-region specific signals |
Klunk WE, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B (PiB). Brain. 2004. ↩︎
Navitsky M, et al. Standardization of amyloid quantitation with florbetapir PET to the Centiloid scale. NeuroImage. 2018. ↩︎
Fleisher AS, et al. Tau PET imaging: optimizing detection and quantification. Alzheimer's & Dementia. 2024. ↩︎
Palmqvist S, et al. Performance of Fully Automated Plasma p-Tau217 Assays as Screening Tests for Alzheimer Disease. JAMA Neurology. 2024. ↩︎
Blennow K, et al. Blood biomarkers for Alzheimer's disease: current status and future directions. Lancet Neurology. 2024. ↩︎
Jack CR Jr, et al. AT(N): A Research Framework for Alzheimer's Disease. Alzheimer's & Dementia. 2022. ↩︎